Read AMCP's summary of the Medicare Coverage of Innovative Technology proposed rule that would provide a national coverage pathway for breakthrough devices, including digital therapeutics.
AMCP submitted comments to the National Academies of Science, Engineering, and Medicine’s draft Preliminary Framework for COVID-19 Vaccine detailing our support to recognize pharmacists as front-line health care workers and pharmacies be included in the vaccine distribution and allocation plans.
AMCP signed on to joint comments on the National Academies of Science, Engineering, and Medicine’s draft Preliminary Framework for COVID-19 Vaccine, advocating for the inclusion of pharmacists as front line health care workers.
AMCP sent a letter to HHS Secretary Azar detailing our concerns with the recent Executive Order that would make changes to the anti-kickback statute safe harbor for manufacturer rebates and the potential for increased costs for patients.
AMCP signed on to a joint letter with other Medicare program stakeholders to HHS Secretary Azar detailing concerns with a recent Executive Order that would make changes to the anti-kickback safe harbor for manufacturer rebates and increase costs for patients.
AMCP joined with other national pharmacy stakeholders to thank HHS Secretary Azar for the agency's authorization of pharmacist administration of children's vaccines.
On August 4, 2020, CMS issued a request for information on implementation of requirements for electronic prescribing of controlled substances in Medicare Part D. Please send any feedback to advocacy@amcp.org by September 25.
AMCP submitted comments on a CMS proposed rule making changes to the Medicaid Drug Rebate Program to account for prescription drug value-based purchasing arrangements.
AMCP joined with other national pharmacy stakeholders to urge HHS to authorize pharmacists to order and administer COVID-19 vaccines when they become available.
AMCP joined with other health care stakeholders to urge Congressional leadership to bolster Medicaid funding due to the COVID-19 public health emergency.
CMS outlining proposed changes to the calculation of best price under the Medicaid Drug Rebate Program (MDRP), particularly how manufacturers should account for value-based purchasing programs.
On June 1, 2020, the FDA issued a RFI requesting stakeholder comments on updating and improving the Orange Book. Please send any feedback to advocacy@amcp.org by August 14, 2020.
On June 1, 2020, the FDA issued a RFI soliciting stakeholder input on the listing of patent information in the Orange Book, including on the types of patent currently listed and how changes to current patent listing practices may impact drug product development. Please send any feedback to advocacy@amcp.org by August 14, 2020.
AMCP joined with national pharmacy stakeholder organizations in issuing a statement of commitment to advocate against racial injustice and all forms of discrimination and to work to eliminate the resulting inequities in patient care.
AMCP submitted comments on CMS’s interim final rule making changes to the Medicare Advantage and Part D programs in response to the COVID-19 public health emergency focused on the provision of telehealth services to Medicare beneficiaries.
AMCP joined with organizations representing of America’s pharmaceutical supply and payment chain to release new policy principles promoting undisrupted patient access to medications during the COVID-19 pandemic.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to its Information Collection Request titled “Medication Therapy Management Improvements – Standardized Format (CMS-10396)” published on February 18, 2020.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the FDA/Federal Trade Commission (FTC) Workshop on a Competitive Marketplace for Biosimilars, held on March 9, 2020.